NeoLumina
Press Releases
NeoLumina BioScience Preparing to Begin a Phase 2 Clinical Trial of Innovative Psilocybin-Based Therapy for Binge Eating Disorder
NeoLumina BioScience Preparing to Begin a Phase 2 Clinical Trial of Innovative Psilocybin-Based Therapy for Binge Eating DisorderVANCOUVER, BRITISH COLUMBIA / July 17, 2025 / NeoLumina BioScience Inc., a pioneering clinical-stage biopharmaceutical company dedicated to...
NeoLumina BioScience to Initiate Strategic Collaboration for Novel Psilocin Delivery System to Advance Mental Health Treatment
NeoLumina BioScience to Initiate Strategic Collaboration for Novel Psilocin Delivery System to Advance Mental Health TreatmentVANCOUVER, BRITISH COLUMBIA / July 17, 2025/ NeoLumina BioScience Inc., a pioneering clinical-stage biopharmaceutical company dedicated to...
NeoLumina Bioscience In-Licenses Clinical-stage Psilocybin Product Candidate from Filament Health for Eating Disorders
NeoLumina Bioscience In-Licenses Clinical-stage Psilocybin Product Candidate from Filament Health for Eating DisordersPEX010 expands NeoLumina’s psychedelic product pipeline. Funding activity in process to advance clinical development. VANCOUVER, BRITISH COLUMBIA,...
NeoLumina Bioscience Advancing Development of Proprietary Psychedelic-based Therapeutic Medicines
NeoLumina Bioscience Advancing Development of Proprietary Psychedelic-based Therapeutic MedicinesFunding activity initiated to advance lead psilocybin-based product candidate into human studies VANCOUVER, BC (August 30, 2023) – NeoLumina Bioscience Inc. (“NeoLumina”...
